Filing Flows › Health Care › AIM ImmunoTech (AIM)
AIM ImmunoTech (AIM) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 7, 2026 · AIM ImmunoTech (AIM) Q2 2026 earnings results →
Q2 2026 Revenue up 4% year over year to $26K
AIM ImmunoTech made $26K in Q2 2026 (+4% Y/Y). Operating margin n/m, net loss $3.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 7, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $26K in Q2 2026, up 4% year over year and up 18% from the previous quarter.
Operating costs exceeded revenue by $3.5M, an operating margin of -13511.5%. Total costs grew 32% against revenue growth of 4%. The fastest-growing cost line was General & admin (+98%). The quarter ended with a net loss of $3.8M, wider than the previous quarter's $3.0M loss.
Operating cash flow was −$4.6M. Non-cash charges added back $44K of depreciation and amortization. Working capital and other items used $846K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 7, 2026 | $26K | +4% | n/m | −$3.8M | −$4.6M |
| Q1 2026 | 10-Q | May 15, 2026 | $22K | +38% | n/m | −$3.0M | −$2.7M |
| Q4 2025 | 10-K | Mar 27, 2026 | $21K | -53% | n/m | −$4.2M | −$2.0M |
| Q3 2025 | 10-Q | Nov 17, 2025 | $26K | -26% | n/m | −$3.3M | −$5.1M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $25K | -50% | n/m | −$2.8M | −$1.5M |
| Q1 2025 | 10-Q | May 15, 2025 | $16K | -60% | n/m | −$3.7M | −$2.4M |
| Q4 2024 | 10-K | Mar 27, 2025 | $45K | -31% | n/m | −$6.0M | −$4.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About AIM ImmunoTech
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.
In its own words, from its 8-K, filed Aug 10, 2026.
AIM ImmunoTech against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +4% against the peers' median +11%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| AIM AIM ImmunoTech | Q2 2026 | $26K | +4% | n/m |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: AIM ImmunoTech 10-Q on SEC EDGAR · CIK 946644 · Biological Products, (No Diagnostic Substances)
13F: who owns AIM and who is buying
More on AIM
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results